FRM
AVEO

Fore Research & Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Fore Research & Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$111K Buy
+5,000
New +$39.4K 0.05% 46
2014
Q3 		– Sell
-67,420
Closed -$1.23M – 106
2014
Q2 		$1.23M Buy
+67,420
New +$877K 0.04% 57

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Fore Research & Management's AVEO Position: Q2 2017 in Review

Fore Research & Management opened a new position in AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2017: 5,000 shares worth $111K. The stake represents 0.05% of the portfolio and ranks #46 among its holdings. This is a return to the name: Fore Research & Management previously reported a position in AVEO as recently as Q2 2014.

Fore Research & Management first reported a position in AVEO in Q2 2014 and has held it in 2 quarters since. The position peaked at $1.23M in Q2 2014. 49 funds tracked by Wall St. Rank hold AVEO as of Q2 2017.

  • Fore Research & Management held 5,000 shares of AVEO Pharmaceuticals, Inc. worth $111K as of Q2 2017.
  • AVEO Pharmaceuticals, Inc. was a new Fore Research & Management position in Q2 2017.
  • AVEO Pharmaceuticals, Inc. made up 0.05% of Fore Research & Management's portfolio in Q2 2017, its #46 holding.
  • Fore Research & Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2014 and has held it in 2 quarters since.
  • Fore Research & Management's AVEO Pharmaceuticals, Inc. position peaked at $1.23M in Q2 2014.
  • 49 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2017.

Based on Fore Research & Management's 13F filing for Q2 2017, filed 14 Aug 2017.